| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 7, 2003
Accepted on June 13, 2003
From Tokyo Medical and Dental University Graduate School, Vascular Medicine and Geriatrics, Tokyo, Japan.
* To whom correspondence should be addressed. E-mail: k.shimoka.vasc{at}tmd.ac.jp.
Objective--To clarify the role of very low density lipoprotein (VLDL) and apolipoprotein E (apoE) in adipogenesis, we studied newly developed hyperlipidemic obese (ob/ob;apoE-/-) mice. Because hydrolysis of VLDL is believed to be the major source of adipogenic free fatty acids, a higher plasma level of VLDL in these mice should exaggerate obesity.
Methods and Results--However, when fed a high-fat, high-cholesterol diet, ob/ob;apoE-/- mice did not show increased body weight or an increased amount of adipose tissue in spite of increased plasma VLDL levels, whereas ob/ob mice showed an increased body weight and amount of adipose tissue, suggesting that there is a novel apoE-dependent pathway for adipogenesis. In vitro experiments using bone marrow stromal cells and 3T3-L1 cells confirmed this notion. ApoE-deficient VLDL did not induce adipogenesis, whereas normal VLDL induced adipogenesis in these cells. The incubation of apoE-deficient VLDL with recombinant human apoE restored its adipogenic activity. Tetrahydrolipstatin, a lipoprotein lipase inhibitor, did not affect the adipogenic activity of VLDL, suggesting that hydrolysis of VLDL did not play a major role in its effects.
Conclusions--In fact, lipid components of VLDL or free fatty acids induced only partial adipogenesis. Our findings indicate that VLDL induces adipogenesis in an apoE-dependent manner both in vitro and in vivo.
This article has been cited by other articles:
![]() |
Z. H. Huang, R. D. Minshall, and T. Mazzone Mechanism for Endogenously Expressed ApoE Modulation of Adipocyte Very Low Density Lipoprotein Metabolism: ROLE IN ENDOCYTIC AND LIPASE-MEDIATED METABOLIC PATHWAYS J. Biol. Chem., November 13, 2009; 284(46): 31512 - 31522. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takazawa, T. Yamauchi, A. Tsuchida, M. Takata, Y. Hada, M. Iwabu, M. Okada-Iwabu, K. Ueki, and T. Kadowaki Peroxisome Proliferator-activated Receptor {gamma} Agonist Rosiglitazone Increases Expression of Very Low Density Lipoprotein Receptor Gene in Adipocytes J. Biol. Chem., October 30, 2009; 284(44): 30049 - 30057. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. H. Huang, D. Gu, and T. Mazzone Role of adipocyte-derived apoE in modulating adipocyte size, lipid metabolism, and gene expression in vivo Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1110 - E1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Getz and C. A. Reardon Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall J. Lipid Res., April 1, 2009; 50(Supplement): S156 - S161. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Pendse, J. M. Arbones-Mainar, L. A. Johnson, M. K. Altenburg, and N. Maeda Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond J. Lipid Res., April 1, 2009; 50(Supplement): S178 - S182. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Atkinson, K. R. Coenen, M. R. Plummer, M. L. Gruen, and A. H. Hasty Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E284 - E290. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Hofmann, D. Perez-Tilve, T. M. Greer, B. A. Coburn, E. Grant, J. E. Basford, M. H. Tschop, and D. Y. Hui Defective Lipid Delivery Modulates Glucose Tolerance and Metabolic Response to Diet in Apolipoprotein E Deficient Mice Diabetes, January 1, 2008; 57(1): 5 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Hausman, C. R. Barb, and R. G. Dean Patterns of gene expression in pig adipose tissue: Transforming growth factors, interferons, interleukins, and apolipoproteins J Anim Sci, October 1, 2007; 85(10): 2445 - 2456. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gao, H. Katagiri, Y. Ishigaki, T. Yamada, T. Ogihara, J. Imai, K. Uno, Y. Hasegawa, M. Kanzaki, T. T. Yamamoto, et al. Involvement of Apolipoprotein E in Excess Fat Accumulation and Insulin Resistance Diabetes, January 1, 2007; 56(1): 24 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. H. Huang, C. A. Reardon, and T. Mazzone Endogenous ApoE Expression Modulates Adipocyte Triglyceride Content and Turnover Diabetes, December 1, 2006; 55(12): 3394 - 3402. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yue, N. Rasouli, G. Ranganathan, P. A. Kern, and T. Mazzone Divergent Effects of Peroxisome Proliferator-activated Receptor {gamma} Agonists and Tumor Necrosis Factor {alpha} on Adipocyte ApoE Expression J. Biol. Chem., November 12, 2004; 279(46): 47626 - 47632. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wassef, L. Bernier, J. Davignon, and J. S. Cohn Synthesis and Secretion of ApoC-I and ApoE during Maturation of Human SW872 Liposarcoma Cells J. Nutr., November 1, 2004; 134(11): 2935 - 2941. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |